X4 Pharma Drug Patent Portfolio
X4 Pharma owns 1 orange book drug protected by 6 US patents Given below is the list of X4 Pharma's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10548889 | Compositions of CXCR4 inhibitors and methods of preparation and use | 11 Dec, 2038 | Active |
| US11045461 | Compositions of CXCR4 inhibitors and methods of preparation and use | 11 Dec, 2038 | Active |
| US12115156 | Compositions of CXCR4 inhibitors and methods of preparation and use | 11 Dec, 2038 | Active |
| US10610527 | Methods for treating immunodeficiency disease | 22 Dec, 2036 | Active |
| US11219621 | Methods for treating immunodeficiency disease | 22 Dec, 2036 | Active |
| US10953003 | Methods for treating cancer | 14 Dec, 2036 | Active |
Latest Legal Activities on X4 Pharma's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of X4 Pharma.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 11 Jul, 2025 | US11219621 |
| Information Disclosure Statement (IDS) Filed | 16 Jun, 2025 | US11219621 |
| transaction for FDA Determination of Regulatory Review Period | 16 Jun, 2025 | US10953003 |
| transaction for FDA Determination of Regulatory Review Period | 16 Jun, 2025 | US10610527 |
| transaction for FDA Determination of Regulatory Review Period | 16 Jun, 2025 | US11219621 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 30 Dec, 2024 | US11045461 |
| Mail Patent eCofC Notification | 10 Dec, 2024 | US12115156 |
| Patent eCofC Notification | 10 Dec, 2024 | US12115156 |
| Email Notification | 10 Dec, 2024 | US12115156 |
| Recordation of Patent eCertificate of Correction | 10 Dec, 2024 | US12115156 |
| Post Issue Communication - Certificate of Correction | 20 Nov, 2024 | US12115156 |
| Second letter to regulating agency to determine regulatory review period | 18 Oct, 2024 | US10953003 |
| Second letter to regulating agency to determine regulatory review period | 18 Oct, 2024 | US11219621 |
| Second letter to regulating agency to determine regulatory review period | 18 Oct, 2024 | US10610527 |
| Patent eGrant Notification | 15 Oct, 2024 | US12115156 |
X4 Pharma's Family Patents
X4 Pharma Drug List
Given below is the complete list of X4 Pharma's drugs and the patents protecting them.
1. Xolremdi
Xolremdi is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10548889 | Compositions of CXCR4 inhibitors and methods of preparation and use |
11 Dec, 2038
(12 years from now)
| Active |
| US11045461 | Compositions of CXCR4 inhibitors and methods of preparation and use |
11 Dec, 2038
(12 years from now)
| Active |
| US12115156 | Compositions of CXCR4 inhibitors and methods of preparation and use |
11 Dec, 2038
(12 years from now)
| Active |
| US10610527 | Methods for treating immunodeficiency disease |
22 Dec, 2036
(10 years from now)
| Active |
| US11219621 | Methods for treating immunodeficiency disease |
22 Dec, 2036
(10 years from now)
| Active |
| US10953003 | Methods for treating cancer |
14 Dec, 2036
(10 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xolremdi's drug page